Healthcare - Biotechnology - NASDAQ - US
$ 0.0002
0 %
$ 941
Market Cap
0.0
P/E
CASH FLOW STATEMENT
-29.6 M
OPERATING CASH FLOW
14.5 M
INVESTING CASH FLOW
21.2 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
eFFECTOR Therapeutics, Inc.
| Net Income | -35.8 M |
| Depreciation & Amortization | 111 K |
| Capital Expenditures | -97 K |
| Stock-Based Compensation | 4.6 M |
| Change in Working Capital | 1.68 M |
| Others | 700 K |
| Free Cash Flow | -29.6 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||
| Net Income | (35.8) | (22.7) | 15.8 | 14.2 | (29.7) |
| Depreciation & Amortization | 0.1 | 53 K | 24 K | 0.2 | 0.3 |
| Deferred Income Tax | 0 | 0 | (0.5) | (0.3) | (2.0) |
| Stock Based Compensation | 4.6 | 5.3 | 8.7 | 0.5 | 0.6 |
| Other Operating Activities | (0.1) | (11.3) | (48.6) | 0.1 | 2.1 |
| Change in Working Capital | 1.7 | 2.7 | (0.2) | (0.8) | 1.1 |
| Cash From Operations | (29.6) | (25.9) | (24.9) | 13.8 | (27.6) |
| INVESTING CASH FLOW | |||||
| Capital Expenditures | 97 K | (0.2) | 42 K | (0.2) | 4 K |
| Other Items | 14.6 | (17.7) | 0.6 | 0 | 88 K |
| Cash From Investing Activities | 14.5 | (17.9) | 0.6 | (0.2) | 84 K |
| FINANCING CASH FLOW | |||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 86 K |
| Total Debt Repaid | 0 | 0 | 5.9 | (2.0) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 56 K | 34 K | 52.9 | 0.1 | 20.2 |
| Cash From Financing Activities | 21.2 | 2.8 | 58.8 | (1.9) | 20.2 |
| CHANGE IN CASH | |||||
| Net Change In Cash | 6.2 | (41.0) | 34.5 | 11.8 | 3.4 |
| FREE CASH FLOW | |||||
| Free Cash Flow | (29.6) | (26.1) | (24.9) | 13.7 | (27.6) |